Ryzneuta Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The ryzneuta market research report is one of a series of new reports that provides ryzneuta market statistics, including the ryzneuta industry global market size, regional shares, competitors with the ryzneuta market share, detailed ryzneuta market segments, market trends, and opportunities, and any further data you may need to thrive in the ryzneuta industry. This ryzneuta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising government initiatives and funding, growing adoption of chemotherapy, a growing trend towards home-based infusion therapy, a growing number of cancer treatment centers, and increasing focus on health and wellness. Major trends in the forecast period include technological advancements in treatment options, advancements in molecular diagnostics and genomic profiling, integrated digital health solutions, innovative combination therapies, and advancements in supportive care therapies.

The rising prevalence of cancer is expected to significantly contribute to the growth of the ryzneuta market in the coming years. Cancer, a group of diseases marked by the uncontrolled growth of abnormal cells, can lead to tumor formation, invasion of nearby tissues, and metastasis to other body parts via the bloodstream or lymphatic system. This increase in cancer cases is largely due to factors such as an aging population, poor lifestyle choices, environmental exposures, genetic factors, improved detection techniques, and chronic inflammation or infections. Ryzneuta addresses cancer by targeting specific growth mechanisms of cancer cells, thereby enhancing the immune response and improving treatment outcomes for cancers such as non-Hodgkin lymphoma. For example, in July 2024, the Australian Institute of Health and Welfare reported a rise in cancer diagnoses in Australia, from 156,781 cases in 2021 to 160,570 in 2022, showing an increase of 3,789 cases in just one year. This growing cancer prevalence is driving the demand for products such as ryzneuta.

A significant development in the ryzneuta market is the introduction of innovative treatments such as efbemalenograstim alfa injections, which aim to address unmet medical needs, boost treatment efficacy, and enhance patient outcomes. Efbemalenograstim alfa is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the duration and incidence of neutropenia, particularly febrile neutropenia, in patients undergoing chemotherapy. In November 2024, Evive Biotech Private Limited, a Singapore-based biopharmaceutical company, teamed up with Acrotech Biopharma LLC, a US-based pharmaceutical firm, to launch Ryzneuta in Germany. This biologic treatment stimulates white blood cell production, helping reduce the risk of infection in patients receiving chemotherapy or other immune-suppressing treatments. The product is expected to play a crucial role in improving patient outcomes, speeding up recovery, and offering an alternative to existing therapies with distinct advantages.

In November 2023, Acrotech Biopharma LLC, entered into a partnership with Evive Biotech Private Limited to commercialize Ryzneuta (Efbemalenograstim alfa) in the United States. As part of the agreement, Evive Biotech granted Acrotech exclusive rights to market and distribute the treatment for chemotherapy-induced neutropenia (CIN) in the US. This partnership strengthens both companies’ presence in the oncology therapeutics market, with Evive Biotech continuing its focus on developing novel biological therapies.

The key Companies operating in the ryzneuta market are Evive Biotech Private Limited, and Acrotech Biopharma LLC.

North America was the largest region in the ryzneuta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ryzneuta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ryzneuta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Ryzneuta (efbemalenograstim alfa) is a long-acting granulocyte colony-stimulating factor (G-CSF) designed to reduce the risk of infection in adults with non-myeloid malignancies undergoing chemotherapy. It works by stimulating the production of neutrophils, a type of white blood cell crucial for fighting infections.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Ryzneuta include chemotherapy-induced neutropenia, cyclic neutropenia, idiopathic neutropenia, and congenital neutropenia. Chemotherapy-induced neutropenia occurs when chemotherapy reduces neutrophil levels, increasing the risk of severe, life-threatening infections due to a weakened immune system. Ryzneuta is available in both parenteral and oral forms and is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It serves a broad range of end users, including hospitals, specialty clinics, home healthcare settings, and research or academic institutes.

The ryzneuta market consists of sales of injectable formulations, combination therapies, pre-filled syringes, autoinjectors, and biosimilar alternatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.